Page last updated: 2024-08-24

atorvastatin and Muscle Disorders

atorvastatin has been researched along with Muscle Disorders in 81 studies

Research

Studies (81)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (1.23)	18.2507
2000's	29 (35.80)	29.6817
2010's	38 (46.91)	24.3611
2020's	13 (16.05)	2.80

Authors

Authors	Studies
Dammen, T; Fagerland, M; Husebye, E; Kristiansen, O; Munkhaugen, J; Peersen, K; Perk, J; Sverre, E; Vethe, NT	1
Asada, M; Bando, T; Chuma, M; Goda, M; Hamano, H; Ishizawa, K; Izawa-Ishizawa, Y; Kondo, Y; Miyata, K; Nakamoto, A; Niimura, T; Okada, N; Takechi, K; Tasaki, Y; Yagi, K; Yanagawa, H; Yoshioka, T; Zamami, Y	1
Bonalume, V; Corsini, A; Greco, MF; Macchi, C; Magnaghi, V; Melfi, V; Mozzo, M; Ruscica, M; Sirtori, CR	1
Duarte-Garcia, A; Harmon, DM; Michet, CJ	1
Bortolotto, LA; de Oliveira, DS; Dos Santos, AM; Hong, VAC; Misse, RG; Pires Borges, IB; Shinjo, SK	1
Güngör, C; Wieshmann, UC	1
English, JD; Isackson, PJ; Linskey, DW; Luzum, JA; Ma, C; Ochs-Balcom, HM; Perry, DA; Vladutiu, GD	1
Barrons, R; Humphries, R; Woods, JA	1
Askarian, F; Hekmatimoghaddam, S; Vahidi, F; Zabihi, M; Zabihi, MS	1
Armitage, J; Beaumont, D; Brack, K; Brooks, L; Goldacre, B; Herrett, E; Hoffman, M; MacDonald, TM; Melrose, P; Moore, M; Perkins, A; Prowse, D; Roberts, I; Shakur-Still, H; Singh, J; Smeeth, L; Thayne, A; van Staa, T; Williamson, E; Wimborne, J	1
Ali, I; Ghaffar, MT; Radhakrishna, A; Whelan, B	1
Hoffmann, TJ; Iribarren, C; Krauss, RM; Lu, B; Medina, MW; Oni-Orisan, A; Risch, N; Seraydarian, M; Sun, L	1
Sparks, DA; Stiles, ZE	1
Moon, TW; Pasha, R	1
Collier, T; Collins, R; Dahlof, B; Gupta, A; Poulter, N; Sever, P; Thompson, D; Whitehouse, A	1
Hofer, M; Hussenbux, A; Steuer, A	1
Armitage, J; Beaumont, D; Brack, K; Goldacre, B; Herrett, E; MacDonald, T; Prowse, D; Roberts, I; Shakur-Still, H; Smeeth, L; Staa, TV; Williamson, E; Youssouf, N	1
Essers, D; Kullak-Ublick, GA; Schäublin, M; Weiler, S	1
Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL	1
Indumathi, B; Katkam, SK; Kutala, VK; Ramakumari, N	1
Aschmann, HE; Kaufmann, M; Puhan, MA; Yebyo, HG	1
Ernste, F; Pitlick, M	1
Gonzalo-Martinez, JF; Herrero-San Martin, A; Ostos-Moliz, F; Sanchez-Tejerina San Jose, D; Toldos-Gonzalez, O	1
Abushahin, A; Hasan, S; Kilani, A; Prayson, R	1
Baggett, MC; Nykamp, D	1
Kang, X; Li, X; Lv, H; Wang, D; Zhang, G; Zhang, L; Zhang, Q	1
Correa, D; Landau, M	1
Åsberg, A; Bogsrud, MP; Hermann, M; Kringen, MK; Piehler, AP; Retterstøl, K; Stormo, C	1
Dabrowski, M; Wiliński, J	1
Laaksonen, R	1
Awoniyi, O; Gosmanov, AR	1
Cunnane, G; Durcan, L; Gleeson, N; McKiernan, S	1
Abdelbaset, M; Agha, AM; Mahmoud, SS; Negm, SA; Safar, MM	1
Abdulghani, HM; Al-Drees, A; Khalil, MS; Khamis, N	1
Dong, B; He, J; Huang, X; Mo, L; Yue, Q	1
Konersman, CG; Mammen, AL; Nichols, L; Pfeifer, K; Shahnoor, N	1
Adámková, V; Češka, R; Dlouhá, D; Hrubá, P; Hubáček, JA; Viklický, O; Vrablík, M; Zlatohlavek, L	1
Aussy, A; Boyer, O; Frigerio, S; Hench, J; Kipfer, S	1
Ballantyne, CM; Brennan, DM; Bruckert, E; Ceška, R; Dent-Acosta, RE; Elliott, M; Gouni-Berthold, I; Lehman, SJ; Lepor, N; Nissen, SE; Preiss, D; Rosenson, RS; Sattar, N; Scott, R; Somaratne, R; Stein, EA; Stroes, E; Wasserman, SM	1
Abdallah, D; El-Ganainy, SO; El-Khatib, AS; El-Mallah, A; Khattab, MM; Mohy El-Din, MM	2
Bründler, J; Oestmann, A; Repond, F	1
Braathen, P; Molden, E; Skovlund, E	1
Auster, S; Betteridge, DJ; Colhoun, HM; Demicco, DA; Durrington, PN; Fuller, JH; Hitman, GA; Neil, HA; Newman, CB; Szarek, M	1
Smith, M; Sullivan, D; Wlodarczyk, J	1
Alt, M; Andrès, E	1
Abel, T; Fehér, J	1
Ali, S; Ginsburg, GS; Reed, CR; Salisbury, BA; Shah, SH; Spasojevic, I; Voora, D	1
Edholm, B	1
Famularo, G; Gasbarrone, L; Minisola, G	1
Brunham, LR; Carleton, BC; Carter, C; Hayden, MR; Hovingh, GK; Jukema, JW; Kastelein, JJ; Lansberg, PJ; Miao, F; Ross, CJ; Stalenhoef, AF; Visscher, H; Zhang, L	1
Åsberg, A; Bogsrud, MP; Hermann, M; Retterstøl, K; Skottheim, IB	1
Chacra, AP; Gagliardi, AC; Krieger, JE; Miname, MH; Pereira, AC; Santos, PC; Santos, RD	1
Teramoto, T	1
Angelica Merlini, P; Antonietta Demola, M; Ardissino, D; Francesca Notarangelo, M; Guidorossi, A; Marziliano, N; Pigazzani, F	1
Gropp, C	1
Arnesen, KE; Bogsrud, MP; Langslet, G; Malt, UF; Ose, L; Retterstøl, K; Sm Stuen, MC; Woldseth, B	1
Bannykh, S; England, JD; Gray, NL; Haas, RH; Hathaway, S; Kimura, BJ; Phillips, PS; Vladutiu, GD	1
Bolognese, MA; Caplan, R; Cressman, M; Hutchinson, H; Raza, A; Schwartz, GG; Tremblay, BP	1
Cartwright, MS; Donofrio, PD; Jeffery, DR; Nuss, GR	1
Burmester, JK; Moore, JH; Wilke, RA	1
McKenney, JM	1
Clarkson, PM; Hittel, D; Hoffman, EP; Thompson, PD; Urso, ML	1
Gibson, E; Luo, D; Newman, C; Szarek, M; Tsai, J	1
Kilkki, E; Kivistö, KT; Niemi, M; Soininen, K; Strandberg, T	1
Jellinek, SP; Mahboobi, SK; Rose, M; Shohat, EZ	1
Asberg, A; Bogsrud, MP; Hermann, M; Mohebi, BU; Molden, E; Ose, L; Retterstøl, K	1
Guthrie, RM	1
Chiesa, G; Cippone, V; Conte Camerino, D; De Luca, A; De Vito, D; Didonna, MP; Frigeri, A; Nicchia, GP; Pierno, S; Pisoni, M; Rizzo, C; Scanziani, E; Sirtori, C; Svelto, M	1
Junni, P; Katajamaa, M; Laaksonen, R; Lehtimäki, T; Lütjohann, D; Oresic, M; Päivä, H; Saarinen, L; Seppänen-Laakso, T; Smet, J; Soini, J; Sysi-Aho, M; Van Coster, R	1
Fabian, V; Knezevic, W; Mastaglia, FL; Needham, M; Panegyres, P; Zilko, P	1
Molden, E; Westergren, T	1
Dande, A; Holford, TR; Kocherla, M; Ruaño, G; Seip, RL; Smith, A; Sorokin, A; Thompson, PD; Windemuth, A; Wu, AH	1
Rosenberg, L; Uretsky, S	1
Hirata, MH; Hirata, RD; Rodrigues, AC	1
Dietz, BL; Oberg, KC	1
Lupattelli, G; Palumbo, B; Sinzinger, H	1
Bellosta, S; Corsini, A; Paoletti, R	1

Reviews

11 review(s) available for atorvastatin and Muscle Disorders

Article	Year
Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 10-12, Volume: 75, Issue:8 Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Daptomycin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Rhabdomyolysis; Rosuvastatin Calcium; Simvastatin; United States; United States Food and Drug Administration	2022
Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. American heart journal, 2019, Volume: 210 Topics: Atorvastatin; Cardiovascular Diseases; Cause of Death; Chemical and Drug Induced Liver Injury; Double-Blind Method; Fluvastatin; Headache; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kidney Diseases; Lovastatin; Middle Aged; Muscular Diseases; Nausea; Neoplasms; Network Meta-Analysis; Placebos; Pravastatin; Randomized Controlled Trials as Topic; Risk Assessment; Rosuvastatin Calcium; Simvastatin; Withholding Treatment	2019
Praxis, 2017, Volume: 106, Issue:1 Topics: Aged; Atorvastatin; Autoantibodies; Diabetes Mellitus, Type 2; Diagnosis, Differential; Disability Evaluation; Humans; Hydroxymethylglutaryl CoA Reductases; Male; Muscle Weakness; Muscular Diseases	2017
Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. The American journal of cardiology, 2008, Dec-15, Volume: 102, Issue:12 Topics: Atorvastatin; Cholesterol, LDL; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Randomized Controlled Trials as Topic; Rosuvastatin Calcium; Sulfonamides	2008
Pitavastatin: clinical effects from the LIVES Study. Atherosclerosis. Supplements, 2011, Volume: 12, Issue:3 Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Cerebrovascular Disorders; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials, Phase IV as Topic; Comorbidity; Diabetes Mellitus, Type 2; Dyslipidemias; Glomerular Filtration Rate; Glycated Hemoglobin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Kidney Diseases; Multicenter Studies as Topic; Muscular Diseases; Prospective Studies; Pyrroles; Quinolines; Risk; Simvastatin; Treatment Outcome; Triglycerides	2011
Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks. The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A Topics: Allylamine; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Colesevelam Hydrochloride; Coronary Artery Disease; Drug Therapy, Combination; Ezetimibe; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Muscular Diseases; Niacin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome	2005
Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. The American journal of cardiology, 2006, Jan-01, Volume: 97, Issue:1 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Albuminuria; Aspartate Aminotransferases; Atorvastatin; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Utilization; Female; Hematuria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pain; Pyrroles; Retrospective Studies	2006
How safe is aggressive statin therapy? Progress in cardiovascular nursing, 2006,Summer, Volume: 21, Issue:3 Topics: Atorvastatin; Chemical and Drug Induced Liver Injury; Drug Interactions; Drug-Related Side Effects and Adverse Reactions; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2006
[Interaction risk with statin switch]. Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2007, Feb-15, Volume: 127, Issue:4 Topics: Anticholesteremic Agents; Anticoagulants; Antihypertensive Agents; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Diltiazem; Drug Interactions; Drug Therapy, Combination; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intracranial Hemorrhages; Muscular Diseases; Pyrroles; Risk Factors; Simvastatin; Warfarin	2007
The genetic determinants of atorvastatin response. Current opinion in molecular therapeutics, 2007, Volume: 9, Issue:6 Topics: Animals; Atorvastatin; Cardiovascular Diseases; Cholesterol; Genetic Variation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lipoproteins, LDL; Muscular Diseases; Pyrroles; Risk Factors	2007
Pharmacological interactions of statins. Atherosclerosis. Supplements, 2002, Volume: 3, Issue:1 Topics: Atorvastatin; Cytochrome P-450 Enzyme System; Drug Interactions; Drug Tolerance; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Lovastatin; Muscular Diseases; Pyrroles; Rhabdomyolysis	2002

Trials

14 trial(s) available for atorvastatin and Muscle Disorders

Article	Year
Clinical and psychological factors in coronary heart disease patients with statin associated muscle side-effects. BMC cardiovascular disorders, 2021, 12-16, Volume: 21, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Coronary Disease; Cross-Over Studies; Cross-Sectional Studies; Double-Blind Method; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Norway; Prevalence; Risk Factors; Treatment Outcome	2021
Safety of Atorvastatin in Patients With Stable Systemic Autoimmune Myopathies: A Pilot Longitudinal Study. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2021, Sep-01, Volume: 27, Issue:6S Topics: Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Longitudinal Studies; Middle Aged; Muscular Diseases; Pyrroles	2021
Statin treatment and muscle symptoms: series of randomised, placebo controlled n-of-1 trials. BMJ (Clinical research ed.), 2021, 02-24, Volume: 372 Topics: Adult; Aged; Aged, 80 and over; Atorvastatin; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Primary Health Care; Symptom Assessment; United Kingdom	2021
Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension p Lancet (London, England), 2017, Jun-24, Volume: 389, Issue:10088 Topics: Adult; Aged; Atorvastatin; Double-Blind Method; Early Termination of Clinical Trials; Female; Hematologic Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertension; Hypolipidemic Agents; Lymphatic Diseases; Male; Middle Aged; Muscular Diseases; Nocebo Effect; Risk Factors; Sleep Wake Disorders; Treatment Outcome	2017
Study protocol for statin web-based investigation of side effects (StatinWISE): a series of randomised controlled N-of-1 trials comparing atorvastatin and placebo in UK primary care. BMJ open, 2017, Dec-01, Volume: 7, Issue:12 Topics: Atorvastatin; Cardiovascular Diseases; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Primary Health Care; Randomized Controlled Trials as Topic; Treatment Outcome; United Kingdom	2017
Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. JAMA, 2016, Apr-19, Volume: 315, Issue:15 Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Atorvastatin; Biomarkers; Cholesterol, LDL; Creatine Kinase; Cross-Over Studies; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Myalgia; Myositis; Rhabdomyolysis; Time Factors	2016
The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes & vascular disease research, 2008, Volume: 5, Issue:3 Topics: Adult; Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gastrointestinal Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ireland; Male; Middle Aged; Muscular Diseases; Practice Guidelines as Topic; Pyrroles; Time Factors; Treatment Outcome; United Kingdom	2008
The SLCO1B15 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology, 2009, Oct-20, Volume: 54, Issue:17* Topics: Aged; Atorvastatin; Creatine Kinase; Female; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Simvastatin	2009
Atorvastatin metabolite measurements as a diagnostic tool for statin-induced myopathy. Molecular diagnosis & therapy, 2011, Aug-01, Volume: 15, Issue:4 Topics: Adult; Aged; Atorvastatin; Biomarkers; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Sensitivity and Specificity	2011
No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy. Scandinavian cardiovascular journal : SCJ, 2013, Volume: 47, Issue:2 Topics: Adult; Aged; Antioxidants; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Prospective Studies; Pyrroles; Selenium; Surveys and Questionnaires; Treatment Outcome; Ubiquinone; Vitamins	2013
Statin-associated myopathy with normal creatine kinase levels. Annals of internal medicine, 2002, Oct-01, Volume: 137, Issue:7 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin	2002
Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. American heart journal, 2004, Volume: 148, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol; Double-Blind Method; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Least-Squares Analysis; Logistic Models; Male; Middle Aged; Muscular Diseases; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Triglycerides	2004
Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arteriosclerosis, thrombosis, and vascular biology, 2005, Volume: 25, Issue:12 Topics: Adolescent; Adult; Atorvastatin; Exercise; Gene Expression Regulation, Enzymologic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscle, Skeletal; Muscular Diseases; Oligonucleotide Array Sequence Analysis; Proteasome Endopeptidase Complex; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Ubiquitin	2005
A systems biology strategy reveals biological pathways and plasma biomarker candidates for potentially toxic statin-induced changes in muscle. PloS one, 2006, Dec-20, Volume: 1 Topics: Atorvastatin; Biomarkers; Computational Biology; Gene Expression; Gene Expression Profiling; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Muscle, Skeletal; Muscular Diseases; Pyrroles; Simvastatin; Systems Biology	2006

Other Studies

56 other study(ies) available for atorvastatin and Muscle Disorders

Article	Year
Impact of Atorvastatin on Skeletal Muscle Mitochondrial Activity, Locomotion and Axonal Excitability-Evidence from International journal of molecular sciences, 2022, May-12, Volume: 23, Issue:10 Topics: Animals; Apolipoproteins E; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Locomotion; Mice; Muscle, Skeletal; Muscular Diseases	2022
76-Year-Old Woman With Generalized Weakness. Mayo Clinic proceedings, 2019, Volume: 94, Issue:12 Topics: Aged; Atorvastatin; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Muscular Diseases	2019
Severe statin-induced autoimmune myopathy successfully treated with intravenous immunoglobulin. BMJ case reports, 2020, May-21, Volume: 13, Issue:5 Topics: Aged; Atorvastatin; Autoimmune Diseases; Diagnosis, Differential; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulins, Intravenous; Male; Muscular Diseases	2020
Association of SLCO1B1 c.521T>C (rs4149056) with discontinuation of atorvastatin due to statin-associated muscle symptoms. Pharmacogenetics and genomics, 2020, Volume: 30, Issue:9 Topics: Atorvastatin; Female; Follow-Up Studies; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Polymorphism, Single Nucleotide; Prognosis; Retrospective Studies; Withholding Treatment	2020
Statin Associated Autoimmune Myonecrosis: Case Report With Delayed Onset and Treatment Challenges. Journal of pharmacy practice, 2022, Volume: 35, Issue:1 Topics: Atorvastatin; Autoantibodies; Autoimmune Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases	2022
Combination of atorvastatin and gemfibrozil plus physical activity: an animal model of statin/fibrate-induced myopathy. Somatosensory & motor research, 2021, Volume: 38, Issue:1 Topics: Animals; Atorvastatin; Disease Models, Animal; Fibric Acids; Gemfibrozil; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Rats	2021
Statin-induced necrotising autoimmune myopathy: a rare complication of statin therapy. BMJ case reports, 2021, Apr-15, Volume: 14, Issue:4 Topics: Atorvastatin; Autoimmune Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscle Weakness; Muscular Diseases	2021
Effect of SLCO1B1 T521C on Statin-Related Myotoxicity With Use of Lovastatin and Atorvastatin. Clinical pharmacology and therapeutics, 2021, Volume: 110, Issue:3 Topics: Aged; Aged, 80 and over; Aging; Atorvastatin; Case-Control Studies; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Lovastatin; Male; Muscular Diseases; Myotoxicity; Phenotype; Polymorphism, Single Nucleotide	2021
Acute Extremity Compartment Syndrome Secondary to Statin-Induced Myopathy. The American surgeon, 2017, Mar-01, Volume: 83, Issue:3 Topics: Anticholesteremic Agents; Atorvastatin; Compartment Syndromes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Leg; Male; Middle Aged; Muscular Diseases; Necrosis	2017
Coenzyme Q10 protects against statin-induced myotoxicity in zebrafish larvae (Danio rerio). Environmental toxicology and pharmacology, 2017, Volume: 52 Topics: Animals; Atorvastatin; F-Box Proteins; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Larva; Locomotion; Muscle Proteins; Muscular Diseases; Protective Agents; RNA, Messenger; Transcription Factors; Ubiquinone; Zebrafish; Zebrafish Proteins	2017
Statin-induced necrotizing autoimmune myopathy: importance of early recognition. British journal of hospital medicine (London, England : 2005), 2017, Jun-02, Volume: 78, Issue:6 Topics: Aged; Atorvastatin; Autoimmune Diseases; Creatine Kinase; Early Diagnosis; Female; Glucocorticoids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle, Skeletal; Muscular Diseases; Necrosis; Prednisolone	2017
Statin-associated immune-mediated necrotizing myopathy: a retrospective analysis of individual case safety reports from VigiBase. European journal of clinical pharmacology, 2019, Volume: 75, Issue:3 Topics: Adverse Drug Reaction Reporting Systems; Atorvastatin; Autoantibodies; Autoimmune Diseases; Creatine Kinase; Databases, Factual; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Necrosis	2019
Clinical features related to statin-associated muscle symptoms. Muscle & nerve, 2019, Volume: 59, Issue:5 Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People	2019
Impact of pharmacogenetics on statin-induced myopathy in South-Indian subjects. Indian heart journal, 2018, Volume: 70 Suppl 3 Topics: Atherosclerosis; Atorvastatin; Cytochrome P-450 CYP3A; DNA; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; India; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Pharmacogenetics; Polymerase Chain Reaction; Polymorphism, Genetic; Rosuvastatin Calcium	2018
Anti-HMGCR myopathy presenting with acute systolic heart failure. BMJ case reports, 2019, May-08, Volume: 12, Issue:5 Topics: Aged; Anti-Inflammatory Agents; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heart Failure, Systolic; Humans; Hydroxymethylglutaryl CoA Reductases; Methylprednisolone; Muscle Weakness; Muscular Diseases; Treatment Outcome	2019
[Toxic myopathy associated with concomitant treatment with atorvastatin and colchicine]. Revista de neurologia, 2019, Jun-01, Volume: 68, Issue:11 Topics: Aged; Arthritis, Gouty; Atorvastatin; Biopsy; Colchicine; Diabetes Mellitus, Type 2; Drug Synergism; Dyslipidemias; Electromyography; Humans; Kidney Failure, Chronic; Male; Muscle, Skeletal; Muscular Diseases; Quadriplegia	2019
When Statins Cause an Autoimmune Response: A Report of a Severe Case of Rhabdomyolysis. The American journal of medicine, 2020, Volume: 133, Issue:1 Topics: Aged; Atorvastatin; Autoantibodies; Autoimmune Diseases; Azathioprine; Creatine Kinase; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunoglobulins, Intravenous; Immunologic Factors; Male; Muscle, Skeletal; Muscular Diseases; Myoglobin; Necrosis; Prednisone; Rhabdomyolysis; Severity of Illness Index	2020
Statin-Associated Bilateral Foot Myopathy. Journal of pharmacy practice, 2020, Volume: 33, Issue:6 Topics: Adult; Atorvastatin; Drug-Related Side Effects and Adverse Reactions; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Rhabdomyolysis	2020
Association of SLCO1B1 and ABCB1 Genetic Variants with Atorvastatin-induced Myopathy in Patients with Acute Ischemic Stroke. Current pharmaceutical design, 2019, Volume: 25, Issue:14 Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; Brain Ischemia; Case-Control Studies; Genotype; Humans; Liver-Specific Organic Anion Transporter 1; Muscular Diseases; Polymorphism, Single Nucleotide; Stroke	2019
Ranolazine-induced myopathy in a patient on chronic statin therapy. Journal of clinical neuromuscular disease, 2013, Volume: 14, Issue:3 Topics: Acetanilides; Aged, 80 and over; Atorvastatin; Drug Interactions; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Piperazines; Pyrroles; Ranolazine	2013
UGT1A128 is associated with decreased systemic exposure of atorvastatin lactone. Molecular diagnosis & therapy, 2013, Volume: 17, Issue:4* Topics: Adult; Alleles; Atorvastatin; Female; Genotype; Glucuronosyltransferase; Heptanoic Acids; Humans; Lactones; Male; Middle Aged; Muscular Diseases; Polymorphism, Genetic; Pyrroles	2013
Safety and tolerability of the use of atorvastatin 40 mg in common daily practice in short-term observation in 3,227 patients. Przeglad lekarski, 2013, Volume: 70, Issue:6 Topics: Anticholesteremic Agents; Atorvastatin; Cardiovascular Diseases; Cholesterol, LDL; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Longitudinal Studies; Male; Middle Aged; Muscular Diseases; Observation; Prospective Studies; Pyrroles; Surveys and Questionnaires	2013
STOMPing forward: statins, muscle complaints and CK. Atherosclerosis, 2013, Volume: 230, Issue:2 Topics: Atherosclerosis; Atorvastatin; Creatine Kinase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscle Weakness; Muscle, Skeletal; Muscles; Muscular Diseases; Myalgia; Pyrroles; Randomized Controlled Trials as Topic	2013
Myopathy after switching from brand to generic atorvastatin. Journal of the American Geriatrics Society, 2013, Volume: 61, Issue:12 Topics: Aged; Atorvastatin; Blood Chemical Analysis; Drugs, Generic; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Muscular Diseases; Polypharmacy; Pyrroles	2013
A benign tumor as the apparent trigger for myopathy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2014, Volume: 20, Issue:2 Topics: Aged; Atorvastatin; Female; Gynecologic Surgical Procedures; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Leg; Leiomyoma; Muscle Weakness; Muscle, Skeletal; Muscular Diseases; Neoplasms; Pyrroles; Treatment Outcome; Uterine Neoplasms	2014
Red yeast rice and coenzyme Q10 as safe alternatives to surmount atorvastatin-induced myopathy in hyperlipidemic rats. Canadian journal of physiology and pharmacology, 2014, Volume: 92, Issue:6 Topics: Animals; Aorta; Atorvastatin; Biological Products; Combined Modality Therapy; Creatine Kinase; Diet, High-Fat; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipoproteins; Liver; Male; Muscular Diseases; Myocardium; Pyrroles; Rats; Ubiquinone	2014
Does coenzyme-Q have a protective effect against atorvastatin induced myopathy? A histopathological and immunohistochemical study in albino rats. Histology and histopathology, 2015, Volume: 30, Issue:3 Topics: Animals; Atorvastatin; bcl-2-Associated X Protein; Creatine Kinase; Cytochromes c; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Muscle, Skeletal; Muscular Diseases; Protective Agents; Pyrroles; Rats; Ubiquinone	2015
Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy. Journal of clinical pharmacy and therapeutics, 2015, Volume: 40, Issue:2 Topics: Aged, 80 and over; Alanine Transaminase; Aspartate Aminotransferases; Atorvastatin; China; Cyclosporine; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Enzyme Repression; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Muscular Diseases; Myoglobin	2015
An Unusual Case of Statin-Induced Myopathy: Anti-HMGCoA Necrotizing Autoimmune Myopathy. Journal of general internal medicine, 2015, Volume: 30, Issue:12 Topics: Acyl Coenzyme A; Atorvastatin; Autoantibodies; Autoimmune Diseases; Creatine Kinase; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscle, Skeletal; Muscular Diseases	2015
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Medical science monitor : international medical journal of experimental and clinical research, 2015, May-20, Volume: 21 Topics: Aged; Atorvastatin; Czech Republic; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Genetic; Muscular Diseases; Myalgia; Obesity; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Smoking	2015
Immune-mediated necrotising myopathy linked to statin use. Lancet (London, England), 2015, Oct-31, Volume: 386, Issue:10005 Topics: Atorvastatin; Autoimmune Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Magnetic Resonance Imaging; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Necrosis	2015
Elucidation of the mechanism of atorvastatin-induced myopathy in a rat model. Toxicology, 2016, 06-01, Volume: 359-360 Topics: Adenosine Triphosphate; Animals; Atorvastatin; Creatine Kinase; Disease Models, Animal; Hydroxymethylglutaryl-CoA Reductase Inhibitors; L-Lactate Dehydrogenase; Lactic Acid; Male; Microscopy, Electron, Transmission; Mitochondria, Muscle; Motor Activity; Muscle, Skeletal; Muscular Diseases; Myoglobin; Pyruvic Acid; Rats; Rats, Sprague-Dawley; Ubiquinone	2016
Rosuvastatin safety: An experimental study of myotoxic effects and mitochondrial alterations in rats. Toxicology letters, 2017, Jan-04, Volume: 265 Topics: Animals; Atorvastatin; Body Weight; Creatine Kinase; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mitochondria, Muscle; Motor Activity; Muscle, Skeletal; Muscular Diseases; Myoglobin; Organ Size; Rats, Sprague-Dawley; Rosuvastatin Calcium; Rotarod Performance Test	2017
Risk management of simvastatin or atorvastatin interactions with CYP3A4 inhibitors. Drug safety, 2008, Volume: 31, Issue:7 Topics: Adult; Aged; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Inhibitors; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Middle Aged; Muscular Diseases; Pyrroles; Risk Management; Simvastatin	2008
[Pubalgia in athlete treated by atorvastatin]. Presse medicale (Paris, France : 1983), 2009, Volume: 38, Issue:4 Topics: Adult; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; France; Heptanoic Acids; Humans; Male; Muscular Diseases; Pelvic Pain; Prednisone; Pyrroles; Recurrence; Sports	2009
[Statin therapy and muscle disorders]. Orvosi hetilap, 2009, Feb-08, Volume: 150, Issue:6 Topics: Atorvastatin; Biological Availability; Cytochrome P-450 Enzyme System; Fatty Acids, Monounsaturated; Fluorobenzenes; Fluvastatin; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Lovastatin; Muscle, Skeletal; Muscular Diseases; Pravastatin; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Sulfonamides	2009
[Statin-induced dysphagia]. Ugeskrift for laeger, 2010, Feb-15, Volume: 172, Issue:7 Topics: Anticholesteremic Agents; Atorvastatin; Deglutition Disorders; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles	2010
Comment and reply on: Atorvastatin: safety and tolerability. Statins and polymyositis: a neglected link? Expert opinion on drug safety, 2010, Volume: 9, Issue:6 Topics: Atorvastatin; Autoimmune Diseases; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Polymyositis; Pyrroles	2010
Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. The pharmacogenomics journal, 2012, Volume: 12, Issue:3 Topics: Adult; Aged; Atorvastatin; British Columbia; Case-Control Studies; Chi-Square Distribution; Female; Gene Frequency; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Netherlands; Odds Ratio; Organic Anion Transporters; Phenotype; Polymorphism, Single Nucleotide; Pyrroles; Risk Assessment; Risk Factors; Severity of Illness Index; Simvastatin	2012
SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. European journal of clinical pharmacology, 2012, Volume: 68, Issue:3 Topics: Adult; Aged; Atorvastatin; Brazil; Female; Genetic Diseases, Inborn; Haplotypes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles	2012
Genetic predisposition to atorvastatin-induced myopathy: a case report. Journal of clinical pharmacy and therapeutics, 2012, Volume: 37, Issue:5 Topics: Aged; Atorvastatin; Coronary Artery Disease; Genetic Predisposition to Disease; Heptanoic Acids; Humans; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Polymorphism, Genetic; Pyrroles	2012
A piece of my mind: A pain in the tuches. JAMA, 2012, Dec-19, Volume: 308, Issue:23 Topics: Anticholesteremic Agents; Atorvastatin; Buttocks; Cardiovascular Diseases; Heptanoic Acids; Humans; Medication Adherence; Mortality, Premature; Muscular Diseases; Pain; Physicians; Pyrroles; Sciatica; Self Care	2012
The HMG Co-A reductase inhibitors ('statins') and myotoxic effects. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2002, Volume: 92, Issue:8 Topics: Atorvastatin; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Muscular Diseases; Myositis; Pravastatin; Pyrroles; Rhabdomyolysis; Simvastatin	2002
Summaries for patients. Muscle abnormalities in four patients taking statins to treat unfavorable cholesterol levels. Annals of internal medicine, 2002, Oct-01, Volume: 137, Issue:7 Topics: Aged; Anticholesteremic Agents; Atorvastatin; Biopsy; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lovastatin; Male; Muscular Diseases; Pain; Pyrroles; Simvastatin	2002
Statin-associated exacerbation of myasthenia gravis. Neurology, 2004, Dec-14, Volume: 63, Issue:11 Topics: Atorvastatin; Cytokines; Dysarthria; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Lovastatin; Male; Middle Aged; Mitochondria; Models, Neurological; Muscular Diseases; Myasthenia Gravis; Neural Conduction; Pravastatin; Pyridostigmine Bromide; Pyrroles; Simvastatin; Th2 Cells; Ubiquinone	2004
Relative impact of CYP3A genotype and concomitant medication on the severity of atorvastatin-induced muscle damage. Pharmacogenetics and genomics, 2005, Volume: 15, Issue:6 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Base Sequence; Case-Control Studies; Creatine Kinase; DNA Primers; Genotype; Heptanoic Acids; Humans; Muscular Diseases; Pyrroles; Risk Factors	2005
Muscle symptoms associated with statins: a series of twenty patients. Basic & clinical pharmacology & toxicology, 2006, Volume: 98, Issue:1 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Creatine Kinase; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pravastatin; Pyrroles; Simvastatin	2006
Systemic infections can decrease the threshold of statin-induced muscle injury. Southern medical journal, 2006, Volume: 99, Issue:4 Topics: Acute Kidney Injury; Aged, 80 and over; Atorvastatin; Bacteremia; Enterococcus faecalis; Escherichia coli; Heart Valve Prosthesis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Muscular Diseases; Pyrroles	2006
Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clinical pharmacology and therapeutics, 2006, Volume: 79, Issue:6 Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Case-Control Studies; Creatine Kinase; Creatinine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Genotype; Heptanoic Acids; Humans; Lactones; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Muscular Diseases; Organic Anion Transporters; Pyrroles	2006
Atorvastatin for stroke prevention. The Medical letter on drugs and therapeutics, 2006, Sep-11, Volume: 48, Issue:1243 Topics: Atorvastatin; Cerebral Hemorrhage, Traumatic; Clinical Trials as Topic; Dose-Response Relationship, Drug; Fluorobenzenes; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Muscular Diseases; Pyrimidines; Pyrroles; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Stroke; Sulfonamides; Time Factors	2006
Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study. British journal of pharmacology, 2006, Volume: 149, Issue:7 Topics: Action Potentials; Animals; Aquaporin 4; Atorvastatin; Body Weight; Chloride Channels; Dose-Response Relationship, Drug; Eating; Fatty Acids, Monounsaturated; Fenofibrate; Fluvastatin; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Kidney Diseases; Lipids; Male; Membrane Potentials; Muscle Contraction; Muscle Fibers, Fast-Twitch; Muscle, Skeletal; Muscular Diseases; Myosin Heavy Chains; Organ Size; Pyrroles; Rats; Rats, Wistar; Rhabdomyolysis; Time Factors	2006
Progressive myopathy with up-regulation of MHC-I associated with statin therapy. Neuromuscular disorders : NMD, 2007, Volume: 17, Issue:2 Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents; Atorvastatin; Creatine Kinase; Female; Folic Acid Antagonists; Genes, MHC Class I; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunohistochemistry; Male; Methotrexate; Middle Aged; Mitochondria, Muscle; Muscle Weakness; Muscular Diseases; Prednisolone; Pyrroles; Sarcolemma; Simvastatin; Up-Regulation	2007
Physiogenomic association of statin-related myalgia to serotonin receptors. Muscle & nerve, 2007, Volume: 36, Issue:3 Topics: Aged; Aged, 80 and over; Atorvastatin; Female; Genomics; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Muscular Diseases; Pain; Polymorphism, Single Nucleotide; Pravastatin; Pyrroles; Receptors, Serotonin; Simvastatin	2007
Letter by Rosenberg and Uretsky regarding article, "Risks associated with statin therapy: a systematic overview of randomized clinical trials". Circulation, 2007, Jul-03, Volume: 116, Issue:1 Topics: Atorvastatin; Biomarkers; Creatine Kinase, MM Form; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Muscular Diseases; Pain; Pyrroles; Randomized Controlled Trials as Topic; Rhabdomyolysis	2007
Judicious evaluation of adverse drug reactions: inaccurate assessment of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced muscle injury. Pharmacotherapy, 1999, Volume: 19, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Atorvastatin; Diagnostic Errors; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Muscular Diseases; Pyrroles; Rhabdomyolysis; Simvastatin	1999
Statin induced myopathy does not show up in MIBI scintigraphy. Nuclear medicine communications, 2001, Volume: 22, Issue:5 Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi	2001